Telmisartan is a new type of antihypertensive drug, which is a specific angiotensin II receptor antagonist for the treatment of essential hypertension. The substitution of angiotensin Ⅱ receptor for at Ⅰ receptor subtype has high affinity binding. Telmisartan has no agonist effect at the at I receptor site, but selectively binds to at I receptor, which is persistent. It has no affinity for other receptors. The function of other receptors mentioned above is unknown, and the possible receptor hyperstimulation effect caused by telmisartan is also unknown. Telmisartan did not inhibit plasma renin or block ion channels. It did not inhibit angiotensin converting enzyme II, which could also degrade bradykinin induced adverse reactions.
Manufacturing
